Abivax Announces Board Change as Key Director Resigns

Abivax SA (FR:ABVX) has released an update.

Abivax SA has announced that Dr. Philippe Pouletty, a key figure in the company’s history and a representative of Truffle Capital, will resign from the Board of Directors as of December 31, 2024. Dr. Pouletty’s departure is linked to his new role as interim Chairman and CEO of another biotechnology company. Despite his resignation, Truffle Capital, a major shareholder, is expected to continue supporting Abivax as it advances its Phase 3 trials of obefazimod for the treatment of ulcerative colitis.

For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.